AcuCort invites investors to meetings in Malmö, Gothenburg and Stockholm on 17-19 November 2026. During the meetings, CEO Jonas Jönmark and Carl Frisk, Strategic Alliance Manager, will present AcuCort's development, the company's international expansion and the upcoming rights issue, followed by a Q&A session.
The roadshow will take place during the subscription period for AcuCort's rights issue, which runs from 12 to 26 November 2026. If fully subscribed, the rights issue may initially generate gross proceeds of approximately SEK 70.3 million before issue costs.
The proceeds are intended to be used, among other things, to fund AcuCort's continued work towards FDA approval for Zeqmelit®, preparations for market entry in the US and continued commercial expansion in existing and new markets.
"We are at an important stage in AcuCort's development and look forward to the opportunity to meet both existing and potential shareholders. During the investor meetings, we will provide further insight into what we have achieved, our priorities going forward and how the rights issue will provide us with the resources to continue executing our strategy," says Jonas Jönmark, CEO of AcuCort.
Zeqmelit® is currently sold in the Nordic region, and AcuCort has a commercial agreement with Glenmark Pharmaceuticals covering six European markets. In parallel, AcuCort is finalising its NDA submission to the US Food and Drug Administration (FDA).
Roadshow
Malmö - 17 November at 17:30
Hotel Savoy, Lilla salen
Opposite Malmö Central Station
Gothenburg - 18 November at 17:30
Elite Park Avenue Hotel, Sandbergsalen
Avenyn
Stockholm - 19 November at 17:30
Investor Studios, Hötorgsskrapa 3, 7th floor
Entrance from Mäster Samuelsgatan 42
Following the presentation and Q&A session, there will be an opportunity for informal networking, with light bites and refreshments.
Places are limited. Registration does not automatically guarantee a place. Confirmation of attendance will be sent by email.
Registration:
https://ir.acucort.se/investerartraffar
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.com
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.